Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2016 Q2- Text added to 2016 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
absence, androyalty, antibiotic, April, Aviragen, broad, challenge, challenged, collectively, Deal, dry, endedMarch, expedite, FASB, Fast, flow, founded, HC, healthcare, Inavir®and, infuture, inthe, intranasally, introduction, mild, monetization, newly, ofInavir®may, ongoingclinical, organization, powder, principle, resupply, shift, simplification, spectrum, Spero, stockpiling, thesale, threeand, threshold, toAviragen, twelve, undisclosed, unmet, withholding, young
Valuein 2016 Q2 filing- Value in 2016 Q3 filing
Original filings
Filing view